-
Cuban tourism in crisis; visitors repelled by fuel, power shortages
-
Liverpool set for Jacquet deal, Palace sign Strand Larsen on deadline day
-
FIFA president Infantino defends giving peace prize to Trump
-
Trump cuts India tariffs, says Modi will stop buying Russian oil
-
Borthwick backs Itoje to get 'big roar' off the bench against Wales
-
Twenty-one friends from Belgian village win €123mn jackpot
-
Mateta move to Milan scuppered by medical concerns: source
-
Late-January US snowstorm wasn't historically exceptional: NOAA
-
Punctuality at Germany's crisis-hit railway slumps
-
Gazans begin crossing to Egypt for treatment after partial Rafah reopening
-
Halt to MSF work will be 'catastrophic' for people of Gaza: MSF chief
-
Italian biathlete Passler suspended after pre-Olympics doping test
-
Europe observatory hails plan to abandon light-polluting Chile project
-
Iran president orders talks with US as Trump hopeful of deal
-
Uncertainty grows over when US budget showdown will end
-
Oil slides, gold loses lustre as Iran threat recedes
-
Russian captain found guilty in fatal North Sea crash
-
Disney earnings boosted by theme parks, as CEO handover nears
-
Sri Lanka drop Test captain De Silva from T20 World Cup squad
-
France demands 1.7 bn euros in payroll taxes from Uber: media report
-
EU will struggle to secure key raw materials supply, warns report
-
France poised to adopt 2026 budget after months of tense talks
-
Latest Epstein file dump rocks UK royals, politics
-
Arteta seeks Arsenal reinforcement for injured Merino
-
Russia uses sport to 'whitewash' its aggression, says Ukraine minister
-
Chile officially backs Bachelet candidacy for UN top job
-
European stocks rise as oil tumbles, while tech worries weigh on New York
-
England captain Itoje on bench for Six Nations opener against Wales
-
Rahm says golfers should be 'free' to play where they want after LIV defections
-
More baby milk recalls in France after new toxin rules
-
Rosenior will not rush Estevao return from Brazil
-
Mercedes ready to win F1 world title, says Russell
-
Germany hit by nationwide public transport strike
-
Barca coach Flick 'not happy' with Raphinha thigh strain
-
WHO chief says turmoil creates chance for reset
-
European stocks rise as gold, oil prices tumble
-
Rink issues resolved, NHL stars chase Olympic gold at Milan
-
S. Korea celebrates breakthrough K-pop Grammy win for 'Golden'
-
Rodri rages that officials 'don't want' Man City to win
-
Gaza's Rafah crossing makes limited reopening after two-year war
-
African players in Europe: Ouattara dents Villa title hopes
-
Liverpool beat Chelsea to Rennes defender Jacquet - reports
-
S. Korea celebrates breakthrough Grammy win for K-pop's 'Golden'
-
Trump says US talking deal with 'highest people' in Cuba
-
Trump threatens legal action against Grammy host over Epstein comment
-
Olympic Games in northern Italy have German twist
-
Bad Bunny: the Puerto Rican phenom on top of the music world
-
Snapchat blocks 415,000 underage accounts in Australia
-
At Grammys, 'ICE out' message loud and clear
-
Dalai Lama's 'gratitude' at first Grammy win
| SCS | 0.12% | 16.14 | $ | |
| CMSC | -0.04% | 23.75 | $ | |
| RIO | 1.4% | 92.325 | $ | |
| CMSD | 0.15% | 24.085 | $ | |
| AZN | -1.86% | 186.965 | $ | |
| RBGPF | 0.12% | 82.5 | $ | |
| BTI | 0.57% | 61.025 | $ | |
| NGG | -1.03% | 84.4 | $ | |
| GSK | 1.42% | 52.345 | $ | |
| BCC | 1.28% | 81.86 | $ | |
| RYCEF | 4.19% | 16.7 | $ | |
| BCE | -0.3% | 25.783 | $ | |
| JRI | 0.53% | 13.15 | $ | |
| RELX | -0.75% | 35.535 | $ | |
| BP | -0.37% | 37.74 | $ | |
| VOD | 1.88% | 14.93 | $ |
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
K.Thomson--BTB